Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Brain ; 144(11): 3291-3310, 2021 12 16.
Article Dans Anglais | MEDLINE | ID: covidwho-1341106


Neuroethical questions raised by recent advances in the diagnosis and treatment of disorders of consciousness are rapidly expanding, increasingly relevant and yet underexplored. The aim of this thematic review is to provide a clinically applicable framework for understanding the current taxonomy of disorders of consciousness and to propose an approach to identifying and critically evaluating actionable neuroethical issues that are frequently encountered in research and clinical care for this vulnerable population. Increased awareness of these issues and clarity about opportunities for optimizing ethically responsible care in this domain are especially timely given recent surges in critically ill patients with prolonged disorders of consciousness associated with coronavirus disease 2019 around the world. We begin with an overview of the field of neuroethics: what it is, its history and evolution in the context of biomedical ethics at large. We then explore nomenclature used in disorders of consciousness, covering categories proposed by the American Academy of Neurology, the American Congress of Rehabilitation Medicine and the National Institute on Disability, Independent Living and Rehabilitation Research, including definitions of terms such as coma, the vegetative state, unresponsive wakefulness syndrome, minimally conscious state, covert consciousness and the confusional state. We discuss why these definitions matter, and why there has been such evolution in this nosology over the years, from Jennett and Plum in 1972 to the Multi-Society Task Force in 1994, the Aspen Working Group in 2002 and the 2018 American and 2020 European Disorders of Consciousness guidelines. We then move to a discussion of clinical aspects of disorders of consciousness, the natural history of recovery and ethical issues that arise within the context of caring for people with disorders of consciousness. We conclude with a discussion of key challenges associated with assessing residual consciousness in disorders of consciousness, potential solutions and future directions, including integration of crucial disability rights perspectives.

Questions bioéthiques , Troubles de la conscience/classification , Neurologie/éthique , , Troubles de la conscience/diagnostic , Humains , SARS-CoV-2
Brain Behav Immun ; 89: 601-603, 2020 10.
Article Dans Anglais | MEDLINE | ID: covidwho-651618


We describe a man whose first manifestations of Creutzfeldt-Jakob disease occurred in tandem with symptomatic onset of coronavirus disease 2019 (COVID-19). Drawing from recent data on prion disease pathogenesis and immune responses to SARS-CoV-2, we hypothesize that the cascade of systemic inflammatory mediators in response to the virus accelerated the pathogenesis of our patient's prion disease. This hypothesis introduces the potential relationship between immune responses to the novel coronavirus and the hastening of preclinical or manifest neurodegenerative disorders. The global prevalence of both COVID-19 and neurodegenerative disorders adds urgency to the study of this potential relationship.

Encéphale/imagerie diagnostique , Infections à coronavirus/complications , Maladie de Creutzfeldt-Jakob/complications , Pneumopathie virale/complications , Sujet âgé , Betacoronavirus , Encéphale/physiopathologie , , Infections à coronavirus/immunologie , Maladie de Creutzfeldt-Jakob/diagnostic , Maladie de Creutzfeldt-Jakob/immunologie , Maladie de Creutzfeldt-Jakob/physiopathologie , Évolution de la maladie , Électroencéphalographie , Fluorodésoxyglucose F18 , Humains , Imagerie par résonance magnétique , Mâle , Pandémies , Pneumopathie virale/immunologie , Tomographie par émission de positons , Radiopharmaceutiques , SARS-CoV-2
Détails de la recherche